Advertisement

Topics

Oryzon Genomics Company Profile

21:41 EDT 21st September 2018 | BioPortfolio

Oryzon genomics is a functional genomics company based in Barcelona, Spain. It was launched in 2001 as a spin-off of the Spanish National Research Council (CSIC) and the University of Barcelona, and has an international staff of 30 highly qualified scientists.

Location

Parc Científic de BarcelonaC/Josep Samitier 1-5
Barcelona
08028
Spain

Contact

Phone: 34 93 403 71 96
Fax: 34 93 403 47 92
Email: info@oryzon.com


News Articles [356 Associated News Articles listed on BioPortfolio]

Oryzon Genomics (ORY) - Awaiting for eventful 2019

Edison Investment Research - Pharmaceutical & healthcare - Oryzon Genomics: The next year is shaping up to be transformative for Oryzon with two data readouts from Phase IIa trials with ORY-2001 in Al...

Edison issues outlook on Oryzon Genomics (ORY)

Dow Jones received a payment from EQS/DGAP to publish this press release. Edison Investment Research Limited Edison issues outlook on Oryzon Genomics (ORY) 18-Jul-2018 / 16:01 GMT/BST London, UK, ...

Oryzon Genomics (ORY) - Phase IIa trial in Alzheimer’s disease initiated

Edison Investment Research - Pharmaceutical & healthcare - Oryzon Genomics: According to the latest news from Oryzon, the first Alzheimer’s disease (AD) patients (3/90) were recruited into the P...

Oryzon Genomics (ORY) - Multiple data readouts in 2019 within cash reach

Edison Investment Research - Pharmaceutical & healthcare - Oryzon Genomics: Oryzon is ramping up its R&D programme and plans to conduct a total of four mid-stage clinical trials with lead assets O...

Could Epigenetics Treat Alzheimer’s? A Spanish Biotech May Give Us Some Answers

Oryzon Genomics will start a clinical trial using a brand new approach with epigenetics to treat Alzheimer’s, which could show promise where many other treatments before have failed. Oryzon Genomics...

Update: Could Epigenetics Treat Alzheimer’s? A Spanish Biotech May Give Us Answers

Update (14/05/2018): Oryzon has been given approval to expand to France its clinical trial for an epigenetic Alzheimer’s drug. The first three patients have already been enrolled in Spain.  Pub...

Oryzon Genomics SA ORY Financial and Strategic SWOT Analysis Review [Report Updated: 09032018] Prices from USD $300

SummaryOryzon Genomics SA Oryzon is a biopharmaceutical company that offers development of epigeneticsbased therapeutics. The company offers epigenetics, a regulatory system that controls gene express...

Genomics England announces appointment of global genomics pioneer as first CEO

Genomics England announces the appointment of its first Chief Executive Officer (CEO) today. Global genomics pioneer Professor John Mattick will join Genomics England in June. He will lead the organiz...

Drugs and Medications [0 Results]

None

Clinical Trials [87 Associated Clinical Trials listed on BioPortfolio]

Electronic Medical Records and Genomics (eMERGE) Phase III

The Electronic Medical Records and Genomics (eMERGE) Network is in its third phase and during this time is enrolling and sequencing 25,000 individuals on a custom sequencing panel of clini...

Genomics and Postoperative Atrial Fibrillation

This research study is done to find out if genetic make up of a person plays a role in complications and recovery after the Coronary Artery Bypass Graft (CABG) operation. As you may be aw...

Microfluidics and Transcriptomics in Post Solid Organ Transplant Patients

The field of genomics is an exciting new field being applied in medicine. Its use in treating some cancers, sepsis and burn patients has been very promising. As knowledge of genomics and a...

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

This pilot clinical trial studies whether using high throughput drug sensitivity and genomics data is feasible in developing individualized treatment in patients with multiple myeloma or p...

Inflammatory Genomics in Human Carotid Artery Disease

To investigate the relationship between genetic variation in genes for inflammation and carotid artery atherosclerosis.

Companies [405 Associated Companies listed on BioPortfolio]

Oryzon Genomics

Oryzon genomics is a functional genomics company based in Barcelona, Spain. It was launched in 2001 as a spin-off of the Spanish National Research Council (CSIC) and the University of Barcelona, and h...

Genomics in Business

In 2003 Keygene initiated the first edition of Genomics in Business. It was the first conference to focus on the existing and future applications of genomics in the Agro-Food industry. With participan...

Genomics One Corporation

Genomics One is a fully integrated biotechnology company committed to the creation of shareholder value through innovation in the fields of genomics, proteomics and mono-clonal antibodies. The mission...

Center for Genomics and Bioinformatics

Center for Genomics and Bioinformatics The Center for Genomics and Bioinformatics (CGB) was launched in 1997 as a new academic department at the Karolinska Institute. Since then, the department has be...

Front Line Genomics

At Front Line Genomics our mission is to help deliver the benefits of genomics faster. Through our website, our magazine and the Festivals of Genomics, we support scientists, clin...

More Information about "Oryzon Genomics" on BioPortfolio

We have published hundreds of Oryzon Genomics news stories on BioPortfolio along with dozens of Oryzon Genomics Clinical Trials and PubMed Articles about Oryzon Genomics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oryzon Genomics Companies in our database. You can also find out about relevant Oryzon Genomics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record